Bison Wealth LLC Invests $213,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bison Wealth LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 524 shares of the pharmaceutical company’s stock, valued at approximately $213,000.

Several other large investors have also added to or reduced their stakes in VRTX. OFI Invest Asset Management acquired a new position in Vertex Pharmaceuticals during the third quarter worth $25,000. Arlington Trust Co LLC boosted its holdings in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares during the last quarter. Compass Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at $29,000. Fortitude Family Office LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at $30,000. Finally, Baystate Wealth Management LLC lifted its stake in Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity

In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares in the company, valued at approximately $31,819,732.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares in the company, valued at approximately $31,819,732.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock worth $5,203,249 in the last quarter. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ VRTX opened at $393.10 on Thursday. The company has a market capitalization of $101.60 billion, a P/E ratio of 28.30, a price-to-earnings-growth ratio of 1.84 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 52-week low of $316.43 and a 52-week high of $448.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The company’s 50 day moving average price is $414.76 and its 200-day moving average price is $396.76.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same quarter in the previous year, the business posted $3.33 EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on VRTX. Wells Fargo & Company increased their price target on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target for the company in a research note on Thursday, April 11th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday. Robert W. Baird cut shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price for the company. in a research note on Wednesday, January 31st. Finally, Maxim Group cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $424.62.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.